Another arrow in the NASH quiver?

In The Lancet Gastroenterology & Hepatology, Rohit Loomba and colleagues1 evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of multiple ascending doses of pegozafermin, a glycoPEGylated FGF21 analogue, in a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study in participants with biopsy-confirmed non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) and a high risk of NASH.